

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alan John Taylor
Date of last notice	4 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
Date of change	20 November 2024

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change: Dr Alan Taylor</p> <p>A.C.N 136 437 913 Pty Ltd ATF the Taylor Family Trust</p> <p>Sally Taylor (spouse of Dr Taylor)</p>	<ul style="list-style-type: none"> • 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025 • 1,083,226 options exercisable at \$0.508 each on or before 24 November 2027 • 1,134,630 options exercisable at \$0.793 each on or before 24 November 2028 • 630,351 options exercisable at \$0.721 each on or before 24 November 2028 • 1,626,778 fully paid ordinary shares • 13,266,660 fully paid ordinary shares • 800,000 fully paid ordinary shares
<p>Class</p>	<p>Options and Shares</p>
<p>Number acquired</p>	<ul style="list-style-type: none"> • 258,246 options exercisable at \$5.505 each on or before 20 November 2029 (Component A) • 482,502 options exercisable at \$5.005 each on or before 20 November 2029 (Component B)
<p>Number disposed</p>	<p>N/A</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<ul style="list-style-type: none"> • Component A: Indicative value of \$680,400 using a Black-Scholes valuation using the 5-day VWAP of shares at 28 June 2024. • Component B: Indicative value of \$1,360,800 using a Monte Carlo simulation using the 5-day VWAP of shares at 28 June 2024.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change Dr Alan Taylor</p>	<ul style="list-style-type: none"> • 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025 • 1,083,226 options exercisable at \$0.508 each on or before 24 November 2027 • 1,134,630 options exercisable at \$0.793 each on or before 24 November 2028 • 630,351 options exercisable at \$0.721 each on or before 24 November 2028 • 1,626,778 fully paid ordinary shares • 258,246 options exercisable at \$5.505 each on or before 20 November 2029 • 482,502 options exercisable at \$5.005 each on or before 20 November 2029
<p>A.C.N 136 437 913 Pty Ltd ATF the Taylor Family Trust</p>	<ul style="list-style-type: none"> • 13,266,660 fully paid ordinary shares
<p>Sally Taylor (spouse of Dr Taylor)</p>	<ul style="list-style-type: none"> • 800,000 fully paid ordinary shares
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of options following approval at the Company's 2024 Annual General Meeting</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest after change	n/a
------------------------------	-----

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Colin David Biggin
Date of last notice	4 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	n/a
Date of change	20 November 2024
No. of securities held prior to change	<ul style="list-style-type: none"> • 4,334,085 fully paid ordinary shares • 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025. • 837,855 options exercisable at \$0.508 each on or before 24 November 2027 • 557,393 options exercisable at \$0.793 each on or before 24 November 2028 • 371,595 options exercisable at \$0.721 each on or before 24 November 2028
Class	Options and Shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Number acquired</p>	<ul style="list-style-type: none"> • 99,679 options exercisable at \$5.505 each on or before 20 November 2029 (Component A) • 186,239 options exercisable at \$5.005 each on or before 20 November 2029 (Component B)
<p>Number disposed</p>	<p>N/A</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<ul style="list-style-type: none"> • Component A: Indicative value of \$262,625 using a Black-Scholes valuation using the 5-day VWAP of shares at 28 June 2024. • Component B: Indicative value of \$525,250 using a Monte Carlo simulation using the 5-day VWAP of shares at 28 June 2024.
<p>No. of securities held after change</p>	<ul style="list-style-type: none"> • 4,334,085 fully paid ordinary shares • 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025. • 837,855 options exercisable at \$0.508 each on or before 24 November 2027 • 557,393 options exercisable at \$0.793 each on or before 24 November 2028 • 371,595 options exercisable at \$0.721 each on or before 24 November 2028 • 99,679 options exercisable at \$5.505 each on or before 20 November 2029 • 186,239 options exercisable at \$5.005 each on or before 20 November 2029
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of options following approval at the Company's 2024 Annual General Meeting</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Graham Roberts
Date of last notice	4 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
Date of change	20 November 2024
No. of securities held prior to change: Christopher Roberts Cabbit Pty Ltd ATF the Robwill Trust	<ul style="list-style-type: none"> • 200,000 fully paid ordinary shares • 17,911,280 fully paid ordinary shares
Class	Options and Shares
Number acquired	17,080, options exercisable at \$5.505 each on or before 20 November 2029
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Indicative value of \$93,018 using a Black-Scholes valuation using the 5-day VWAP of shares at 7 October 2024.

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change Christopher Roberts	<ul style="list-style-type: none"> 200,000 fully paid ordinary shares 17,080, options exercisable at \$5.505 each on or before 20 November 2029
Cabbit Pty Ltd ATF the Robwill Trust	<ul style="list-style-type: none"> 17,911,280 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options following approval at the Company's 2024 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	n/a
---	-----

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michelle Parker
Date of last notice	4 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
Date of change	20 November 2024
No. of securities held prior to change:	<ul style="list-style-type: none">• 1,077,710 fully paid ordinary shares• 500,000 options exercisable at \$0.9375 each on or before 01 July 2025• 316,868 options exercisable at \$0.508 each on or before 01 July 2027• 270,279 options exercisable at \$0.79 each on or before 01 July 2028• 66,089 options exercisable at \$5.505 each on or before 01 July 2029

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Options and Shares
Number acquired	<ul style="list-style-type: none"> • 20,987 options exercisable at \$8.7703 each on or before 20 November 2029 (Component A) • 151,369 options exercisable at \$7.973 each on or before 20 November 2029 (Component B)
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ul style="list-style-type: none"> • Component A: Indicative value of \$88,500 using a Black-Scholes valuation using the 5-day VWAP of shares at 9 October 2024. • Component B: Indicative value of \$525,250 using a Monte Carlo simulation using the 5-day VWAP of shares at 9 October 2024.
No. of securities held after change	<ul style="list-style-type: none"> • 1,077,710 fully paid ordinary shares • 500,000 options exercisable at \$0.9375 each on or before 01 July 2025 • 316,868 options exercisable at \$0.508 each on or before 01 July 2027 • 270,279 options exercisable at \$0.79 each on or before 01 July 2028 • 66,089 options exercisable at \$5.505 each on or before 01 July 2029 • 20,987 options exercisable at \$8.7703 each on or before 20 November 2029 • 151,369 options exercisable at \$7.973 each on or before 20 November 2029
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of options following approval at the Company's 2024 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Rosanne Elizabeth Robinson
Date of last notice	18 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	n/a
Date of change	20 November 2024
No. of securities held prior to change	178,079 fully paid ordinary shares
Class	Options and Shares
Number acquired	17,080, options exercisable at \$5.505 each on or before 20 November 2029
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Indicative value of \$93,018 using a Black-Scholes valuation using the 5-day VWAP of shares at 7 October 2024.

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none">• 178,079 fully paid ordinary shares• 17,080, options exercisable at \$5.505 each on or before 20 November 2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options following approval at the Company's 2024 Annual General Meeting

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Thomas Ramdahl
Date of last notice	4 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
Date of change	20 November 2024
No. of securities held prior to change	• 720,000 ordinary shares
Class	Options and Shares
Number acquired	17,080, options exercisable at \$5.505 each on or before 20 November 2029
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Indicative value of \$93,018 using a Black-Scholes valuation using the 5-day VWAP of shares at 7 October 2024.

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> 720,000 ordinary shares 17,080, options exercisable at \$5.505 each on or before 20 November 2029
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of options following approval at the Company's 2024 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.